NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress
Rhea-AI Summary
NuGen Medical Devices (TSXV: NGMDF) provided a 2025 year-end update outlining R&D, technical, clinical, and commercial progress across its needle-free subcutaneous drug-delivery programs.
Key 2025 achievements include feasibility of a Ready-to-Fill Nozzle, advancement of a next-generation variable-dose jet injector, pressure-profile optimization, prototype progress on a patented refill cartridge system, and development of an animal-use PetJet injector.
Operational expansions included a Netherlands design hub, two MedTech hires in China, clinical team growth in France, Brazil and Malaysia, formation of a Medical Advisory Board, UK launch of the EZIAUTOJECTOR with NHS Drug Tariff approval, and ongoing distributor and payer engagement in Mexico, Asia and Canada.
Positive
- NHS Drug Tariff approval for UK private-label EZIAUTOJECTOR
- Feasibility demonstrated for Ready-to-Fill Nozzle component
- Advanced next-generation variable-dose jet injector development
- Pressure-profile optimization initiated to improve injection comfort
- Expanded design hub in Netherlands and two MedTech hires in China
- Clinical team expansion in France, Brazil, and Malaysia
Negative
- None.
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is providing a summary of key developments achieved during 2025 across its Research and Development programs, technical capabilities, clinical initiatives, and global commercial activities.
2025 Operational Highlights
Research & Development
Demonstrated feasibility of the Ready-to-Fill Nozzle, (a component used in sterile, ready-to-use pharmaceutical filling systems designed to support prefilled drug formats), supporting development of a prefilled solution targeted for future integration.
Advanced the next-generation variable-dose jet injector to better align with clinical practice and reduce training requirements.
Initiated pressure-profile optimization work to improve injection comfort and consistency.
Progressed prototypes for the Company's patented refill system designed for direct cartridge storage.
Advanced an animal-use injector to be released under the PetJet™ brand.
Technical & Engineering Capacity
Expanded the Netherlands design hub with new roles supporting pharma-focused device development.
Added two MedTech specialists in China to strengthen testing, validation, and cost-effective development execution.
Clinical & Medical Engagement
Expanded the clinical team in France, Brazil, and Malaysia to support real-world evidence generation, local evaluations, and patient-experience initiatives.
Initiated the formation of a Medical Advisory Board to guide product relevance and clinical alignment.
Commercial & Market Activity
United Kingdom: Launched the EZIAUTOJECTOR® private-label device and secured NHS Drug Tariff approval.
Mexico, Asia, and Canada: Continued distributor engagement, clinician feedback collection, and insurance coverage discussions.
Supporting Sol Millennium Medical Group's upcoming participation at Pharmapack Europe 2026, highlighting NuGen's needle-free technology.
"Our progress in 2025 reflects the disciplined work of our teams across R&D, clinical development, and global market engagement," said Liang Lin, CEO of NuGen Medical Devices Inc. "The advancements made this year strengthen our foundation and support the continued evolution of our needle-free technology."
About NuGen Medical Devices
NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide.
Websites: insujet.com | insujet.fr | nugenmd.com
LinkedIn: https://www.linkedin.com/company/nugen-medical-devices
Investor Relations: IR@nugenmd.com
For further information, please contact:
Liang Lin, Chief Executive Officer
+ 1-833-867-5557
ir@nugenmd.com
Notice Regarding Forward-Looking Information:
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280669
FAQ
What did NuGen (NGMDF) announce in its January 16, 2026 2025 year-end update?
Does NuGen (NGMDF) have regulatory approval for its UK device?
What product development milestones did NuGen (NGMDF) report for 2025?
Where did NuGen (NGMDF) expand technical and clinical capacity during 2025?
Will NuGen (NGMDF) be represented at Pharmapack Europe 2026?
Did NuGen (NGMDF) announce any commercial activities in Mexico, Asia, or Canada?
